Description
LDK-378 is an anaplastic lymphoma kinase (ALK) inhibitor that displays anticancer chemotherapeutic activity. LDK-378 is used to treat ALK-positive non-small cell lung cancer (NSCLC), particularly in subjects experiencing resistance to crizotanib. This compound also inhibits IGF-1R.